BAX · Baxter International Inc.

The thesis

Baxter International's remaining case is an operating recovery, and the third-quarter report on 29 October 2026 settles whether it is repeatable. The shares closed at $24.70 on 21 October 2026, back above the $24 level that the July guidance-led re-rating failed on 11 September 2026 (weekly close $23.80), but still 12.8% below the 52-week high of $28.34.

The narrative is maturing: the story is well known, and the only company news since the 25 August 2026 recall is the 8 October 2026 announcement of the earnings call date. On 30 July 2026, Baxter reported second-quarter sales of $2.96 billion, up 5% organically. Adjusted diluted earnings per share (EPS) of $0.56 fell 5% year over year and included a $0.11-per-share tariff-refund benefit. Baxter raised full-year 2026 guidance to 2–3% organic sales growth and $1.95–$2.15 adjusted diluted EPS, and reiterated it on 19 August 2026.

The improvement is unproven because earnings fell while sales grew. A third-quarter adjusted EPS increase year over year would weaken that reading. Another decline would confirm it.

The call is scheduled for 29 October 2026 at 7:30 a.m. Central Time. It is the first quarter presented under chief financial officer John Rogers, whose appointment took effect 1 October 2026.

Bullish and bearish views on Baxter International Inc.

The bull case on Baxter International Inc. (BAX), in brief: Organic demand improved in July. The bear case: Earnings lagged sales growth.

Bull case

• Organic demand improved in July. Baxter's 30 July 2026 release recorded 5% organic sales growth and $181 million of quarterly free cash flow. Third-quarter organic growth below the 2–3% full-year guidance range would weaken this point.
• Inventory cost pressure may ease. At the 9 September 2026 Wells Fargo conference, management identified at least $50 million of second-quarter impact from higher-cost inventory and expected sequential relief. Third-quarter margins showing no relief would contradict that expectation.
• Analysts raised targets after the quarter. TD Cowen lifted its target to $29 from $24 on 31 July 2026. Citi upgraded the shares to Neutral from Sell with a $28 target, up from $17. Stifel raised its target to $28 from $24, and Deutsche Bank's target is $27, up from $20.
• Shares have recovered from the September low. Adjusted daily closes show $24.70 on 21 October 2026, up from $23.90 on 8 October 2026 and from the $23.37 close on 25 September 2026. The shares rose 10.3% over three months.

Bear case

• Earnings lagged sales growth. Adjusted diluted EPS fell 5% to $0.56 on 30 July 2026 despite 5% organic sales growth, and the quarter included a $0.11-per-share tariff-refund benefit. Another year-over-year decline on 29 October 2026 would leave repeatable improvement unproven.
• Product-quality events continue. The FDA classified the removal of certain Duo-Vent solution set lots as Class I on 13 August 2026. Baxter recalled one lot of anticoagulant sodium citrate solution on 25 August 2026 over possible fiberglass particles and reported no related adverse events. A further material recall would strengthen this concern.
• Analyst opinion is neutral. StockAnalysis.com reported a Hold consensus across 15 analysts on 8 October 2026: two Strong Buy, 11 Hold and two Strong Sell. The consensus target of $27 sits 9.3% above the 21 October 2026 close, and the highest published target is $29.
• The report is eight days away. The 29 October 2026 call is the first under a new finance chief, and a reset of the full-year outlook is possible at a transition.

Price setup

Adjusted daily closes show $24.70 on 21 October 2026, 12.8% below the 52-week high of $28.34. The 14-day relative strength index (RSI), a momentum gauge on a 0–100 scale, reads 60.7. The shares have moved from $23.90 on 8 October 2026 to $24.70 ahead of the report.

The $24 weekly-close level, which failed on 11 September 2026, is now under the price. The recent low is the $23.37 close on 25 September 2026. A move back below that close would put the shares under the September low and erase the recovery.

Crowding evidence is limited. The consensus rating is Hold, and no insider or share-issuance filings appeared in the last 30 days. The one observable pressure point is the imminent earnings date.

Catalysts, next 30 days

No other dated company event falls inside the next 30 days.

Elapsed catalysts

• 29 October 2026: Third-quarter 2026 results and conference call at 7:30 a.m. Central Time. It settles whether adjusted EPS improvement is repeatable and whether the $1.95–$2.15 full-year range holds. (passed 8d ago)

What would change the view

The case breaks if Baxter cuts full-year 2026 adjusted diluted EPS guidance below $1.95, or cuts organic sales-growth guidance below 2%. It also breaks if third-quarter adjusted EPS declines year over year again despite positive organic sales growth. A further material FDA recall, Class I classification or warning letter after the 25 August 2026 recall would add to the case against it.

On price, a daily close below $23.37, the 25 September 2026 adjusted close and the recent low, would end the recovery reading. Third-quarter EPS growth with margin relief from inventory costs would strengthen the case.

What it trades with

No published theme cluster carries Baxter, and the shares trade as a single-name situation. The 30 July 2026 re-rating followed company guidance, and the shares moved 8.7% that day according to news reports. The next large move is tied to the 29 October 2026 report. Peer hospital-products and medtech names share the same demand backdrop, but no dated peer data point is cited here.